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Abstract body: 
Background. According to the new medical device regulation (MDR 2017/745), devices employing 
advanced materials containing nanomaterials will be classified as class III and will have to undergo 
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(re-)assessment of risks. To that aim, the Quality-by-Design approach, as defined in ICH Q8-Q11 
(QbD), is indisputably accepted and strongly recommended by the FDA and EMA for risk assessment 
during drug development. Some papers have emphasized the possible implementation of QbD in 
the medical device industry [1].  Nevertheless, to date no real and effective adaptation of this risk-
based quality management approach has been adapted to biomedical devices manufacturing [2].   
Objectives. Our goal is to develop both a new QbD paradigm and a web-based tool devoted to the 
safe development of class-III medical devices containing nanomaterials. This objective is pursued in 
the context of the European H2020 project TBMED (An Open Innovation test bed for the 
development of high-risk medical devices). 
Methods. A six-step QbD approach is proposed. The first four stages are devoted to the preclinical 
development while the next two steps concern the industrial implementation. Three categories of 
risk-assessment methods are used at different development steps: failure mode and effects analysis 
based on prior knowledge, statistical designs of experiments and Bayesian inference. To assess its 
applicability, we applied the integrated QbD approach to the development of a new medical device 
devoted to the realtime control of light during photodynamic therapy using nanoparticle-based 
photosensitizers.  
Results. The new SaaS platform, entitled “Nanologic”, is available at: (www.i-nano.eu). Four key 
documents for regulatory agencies are established during the preclinical study: the target product 
profile, the list of critical quality attributes (quality/safety descriptors), the list of critical material 
attributes and process parameters (risk factors associated with the design and production phases) 
and the design space: a key concept of risk assessment in QbD. 
Conclusion. We show how the QbD best practices can be adapted to the development of medical 
devices containing nanomaterials. Moreover, new questions still have to be investigated such as the 
solutions to be developed to better predict risks associated with the clinical proof of concept. 
Your abstract may additionally contain one important figure and references. Use the space below if 
you want to include one figure. 
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Fig. 1 A Quality-by-Design best practices approach for the safe development of biomedical devices 
containing nanomaterials.    
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